Generate Biomedicines, Inc.

Generate Biomedicines reported a net loss of $129.0 million for the six months ended June 30, 2026, an increase from $101.1 million in the prior year, while collaboration revenue decreased to $13.5 million. The company significantly improved its liquidity position by completing an initial public offering in March 2026, raising $369.3 million in net proceeds. This funding has alleviated previous concerns about its ability to continue as a going concern, with current capital expected to fund operations into the first half of 2028.

Generate Biomedicines reported its second quarter 2026 financial results, with a net loss of $67.3 million and revenue of $6.3 million, both showing a decline compared to the prior year. Despite the financial results, the company highlighted significant pipeline progress, including the advancement of GB-0895 Phase 3 studies in severe asthma and the enrollment of the first cohort in the GB-4362 Phase 1 study. Additionally, a biologic designed with Generate's platform was advanced into Novartis's preclinical pipeline, validating the company's generative biology platform.

Generate Biomedicines reported a net loss of $(61.7) million for the first quarter of 2026, an increase from $(44.3) million in the prior year period, primarily due to higher research and development expenses. The company successfully completed its Initial Public Offering in March 2026, raising net proceeds of $369.3 million, which significantly improved its liquidity position to $516.6 million in cash, cash equivalents, and marketable securities. This capital infusion alleviated previous concerns about the company's ability to continue as a going concern, with current resources expected to fund operations into the first half of 2028.

Generate Biomedicines reported its first quarter 2026 financial results, with cash, cash equivalents, and marketable securities totaling $516.6 million as of March 31, 2026, significantly boosted by $369.3 million net proceeds from its IPO. The company expects this capital to fund operations into the first half of 2028. While revenue decreased to $7.2 million and net loss widened to $61.7 million, Generate made strong progress across its clinical pipeline, including advancing GB-0895 in Phase 3, activating sites for GB-4362 with FDA Fast Track designation, and expecting first patient dosing for GB-5267 in H2 2026.